Skip to search formSkip to main contentSkip to account menu

Spinraza

National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2018
2018
Aim to report the experience in patients with SMA type 1 treated in the Nusinersen expanded access program (EAP) in a single… 
2018
2018
Spinal muscular atrophy (SMA), the most common gentic cause of infantile death caused by mutations in the SMN1 gene, presents a… 
2017
2017
Background Classic proximal 5q-SMA is a progressive motor neuron disorder leading to muscle weakness and atrophy and is the most… 
2017
2017
KEY POINTS Canada is one of the few developed countries without a regulatory framework for orphan drugs.[1][1] Orphan drugs are… 
Review
2017
Review
2017
SMA is a rare hereditary neuromuscular disease that causes weakness and muscle wasting as a result of the loss of spinal motor… 
Review
2017
Review
2017
Cure SMA is dedicated to the treatment and cure of spinal muscular atrophy (SMA)—a disease affecting motor neurons, that robs… 
2016
2016
Gene therapies featured prominently among this year's newsworthy drugs, some of which have already received a green light from…